A major medical journal is currently re-evaluating a 2001 study on Paxil, an antidepressant, amid growing calls for its retraction due to concerns over its credibility and the controversy surrounding its marketing practices.

The study claimed Paxil was safe and effective for adolescents, but subsequent findings revealed that its data were misleading, especially in downplaying serious side effects like suicidal thoughts.

Despite the lack of FDA approval for use in teenagers at the time, the drug's manufacturer, GSK, used the study to promote Paxil to healthcare providers, raising questions about ethical marketing.

The FDA had previously issued warnings about the increased risk of suicidal thoughts associated with SSRIs such as Paxil, adding to the controversy over the drug’s safety and the study’s influence.

The review by the journal highlights ongoing concerns regarding the integrity of the original study and how its publication may have affected prescribing practices and patient safety.